Current stock page

Financial Data

XERS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

XERSXeris Biopharma Holdings, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$16.66+$0.01 (+0.06%)

Latest quote

  • Momentum
    98
  • Value
    68
  • Quality
    71
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$107.23M$92.1M$83.13M$85.81M$74.38M$71.54M$60.12M$60.1M
Gross Profit$94.8M$79.59M$69.84M$66.73M$63.38M$56.93M$51.39M$50.62M
Operating Income$16.92M$5.17M$7.92M$16.77M$6.73M$4.48M-$3.09M$1.68M
Net Income$11.29M-$31.1M$2.23M$11.08M$621K-$1.93M-$9.22M-$5.11M
EPS$0.06-$0.18$0.01$0.07$0-$0.01-$0.06-$0.03
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$35.47M$8.26M$9.87M$20.04M$18.43M$182K-$10.03M$1.98M
Capital Expenditure-$159K-$209K-$325K-$333K-$363K-$279K-$13K-$220K
Free Cash Flow$35.31M$8.05M$9.55M$19.71M$18.07M-$97K-$10.04M$1.76M
Net Cash Provided By Operating Activities$35.47M$8.26M$9.87M$20.04M$18.43M$182K-$10.03M$1.98M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$423.22M$411.91M$392.01M$383.53M$370.19M$334.69M$315.45M$323.06M
Total Debt$226.07M$289.44M$37.33M$37.76M$38.19M$257.22M$268.75M$271.45M
Cash And Cash Equivalents$131.08M$121.75M$111.75M$111.04M$91.6M$59.29M$58.44M$71.62M
Total Liabilities$374.44M$421.64M$379M$369.84M$371.05M$353.99M$350.58M$352.68M
Total Stockholders Equity$48.78M-$9.73M$13.01M$13.69M-$861K-$19.3M-$35.13M-$29.62M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio——98.081,956.74————
P/B ratio59.18—90.5279.19————
P/S ratio8.19———————
Debt To Equity4.63—2.872.76————
Free Cash Flow Yield2.52%4.35%4.01%2.55%0.71%-1.63%-3.49%-6.15%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio——98.081,956.74————
P/B ratio59.18—90.5279.19————
P/S ratio8.19———————
Return On Equity-13.32%—92.29%4.05%————
Debt To Equity4.63—2.872.76————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-415.46x
Pb61.79x
Revenue Growth Yoy44.16%
EPS Growth Yoy1900.00%
Gross Margin84.44%
Operating Margin12.70%
ROE-39.52%
ROIC15.85%
Debt To Equity4.63
FCF Yield2.39%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$16.66
Volume3.4M
RSI (14)85.42
MACD1.74
MACD signal1.17
MACD histogram0.57
ADX (14)47.01
SMA (50)$10.40
SMA (200)$7.83
ATR (14)$0.75
Historical volatility (annualized)110.33%
Volume (20-day average)3.47M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score55/100
Beta0.07
Annual volatility56.97%
Max Drawdown-34.93%
Sharpe Ratio1.67
VaR (95%, 1-day)-4.33%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

XERS Financial Data FAQ

What is Xeris Biopharma Holdings, Inc.'s revenue?

Xeris Biopharma Holdings, Inc.'s revenue is one of the core financial data points for XERS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Xeris Biopharma Holdings, Inc.'s revenue growing?

Revenue growth shows whether Xeris Biopharma Holdings, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is XERS's EPS?

XERS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Xeris Biopharma Holdings, Inc.'s net income?

Xeris Biopharma Holdings, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Xeris Biopharma Holdings, Inc. generate?

Free cash flow shows how much cash Xeris Biopharma Holdings, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Xeris Biopharma Holdings, Inc. have?

Cash and debt help frame XERS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.